
New Therapy Targeting Malignant B Cells
The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq (Polivy), in combination with a rituximab product,...